Phuong N. Huynh

Array ( [id] => 9874717 [patent_doc_number] => 08961981 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-24 [patent_title] => 'Targeting the neuromuscular junction for treatment' [patent_app_type] => utility [patent_app_number] => 13/527142 [patent_app_country] => US [patent_app_date] => 2012-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 7981 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13527142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9529765 [patent_doc_number] => 08753633 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-17 [patent_title] => 'Human antibodies that bind human TNFα' [patent_app_type] => utility [patent_app_number] => 13/524525 [patent_app_country] => US [patent_app_date] => 2012-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 25692 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13524525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8903667 [patent_doc_number] => 20130171170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-04 [patent_title] => 'ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/494845 [patent_app_country] => US [patent_app_date] => 2012-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 89337 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13494845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8637120 [patent_doc_number] => 20130028923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-31 [patent_title] => 'KDR PEPTIDES AND VACCINES COMPRISING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/494930 [patent_app_country] => US [patent_app_date] => 2012-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 13057 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13494930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8566065 [patent_doc_number] => 20120328636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-27 [patent_title] => 'KDR PEPTIDES AND VACCINES COMPRISING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/494933 [patent_app_country] => US [patent_app_date] => 2012-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 13068 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13494933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9245538 [patent_doc_number] => 08609819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-17 [patent_title] => 'Extracellular serine protease' [patent_app_type] => utility [patent_app_number] => 13/486011 [patent_app_country] => US [patent_app_date] => 2012-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 10833 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13486011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8477201 [patent_doc_number] => 20120276608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'Multivalent Immunoglobulin-Based Bioactive Assemblies' [patent_app_type] => utility [patent_app_number] => 13/483761 [patent_app_country] => US [patent_app_date] => 2012-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 50326 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13483761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405388 [patent_doc_number] => 20120237442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'Design and Construction of Novel Multivalent Antibodies' [patent_app_type] => utility [patent_app_number] => 13/480650 [patent_app_country] => US [patent_app_date] => 2012-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39710 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13480650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8382403 [patent_doc_number] => 20120226026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-06 [patent_title] => 'POTENT CONJUGATES AND HYDROPHILIC LINKERS' [patent_app_type] => utility [patent_app_number] => 13/473974 [patent_app_country] => US [patent_app_date] => 2012-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 22967 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13473974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8489090 [patent_doc_number] => 20120288497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-15 [patent_title] => 'COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 13/472862 [patent_app_country] => US [patent_app_date] => 2012-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17424 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13472862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9977683 [patent_doc_number] => 09023994 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-05 [patent_title] => 'Immunoglobulin reduced in thrombogenic agents and preparation thereof' [patent_app_type] => utility [patent_app_number] => 13/470788 [patent_app_country] => US [patent_app_date] => 2012-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21774 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13470788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8865628 [patent_doc_number] => 20130149331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'RHAMNOSE AND FORSSMAN CONJUGATED IMMUNOGENIC AGENTS' [patent_app_type] => utility [patent_app_number] => 13/463420 [patent_app_country] => US [patent_app_date] => 2012-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10350 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13463420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8358618 [patent_doc_number] => 20120213777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-23 [patent_title] => 'VASCULAR ENDOTHELIAL GROWTH FACTOR 2' [patent_app_type] => utility [patent_app_number] => 13/460217 [patent_app_country] => US [patent_app_date] => 2012-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 101256 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13460217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476751 [patent_doc_number] => 20120276158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES' [patent_app_type] => utility [patent_app_number] => 13/457999 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 36089 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13457999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10573096 [patent_doc_number] => 09295718 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-29 [patent_title] => 'Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins' [patent_app_type] => utility [patent_app_number] => 13/458067 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 36667 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13458067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476727 [patent_doc_number] => 20120276134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS' [patent_app_type] => utility [patent_app_number] => 13/458220 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 36124 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13458220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476749 [patent_doc_number] => 20120276156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIER COMPOSITIONS WITH TRANSPLANTABLE GRAFT ANTIGENS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/457962 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 32333 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13457962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476726 [patent_doc_number] => 20120276133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS FOR INDUCING REGULATORY B CELLS' [patent_app_type] => utility [patent_app_number] => 13/458179 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 32061 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13458179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8495480 [patent_doc_number] => 20120294888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-22 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY' [patent_app_type] => utility [patent_app_number] => 13/457977 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 31512 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13457977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476753 [patent_doc_number] => 20120276160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'TOLEROGENIC SYNTHETIC NANOCARRIERS FOR REGULATING INNATE IMMUNE RESPONSES' [patent_app_type] => utility [patent_app_number] => 13/458284 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 31322 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13458284 [rel_patent_id] =>[rel_patent_doc_number] =>)